Drugmakers' shares fell globally after President Trump said he would [sign an executive order]( ...

Shares of pharmaceutical companies declined after U.S. President Donald Trump announced plans to lower U.S. prescription drug ...

England’s drug approval body has resisted pressure from pharmaceutical companies to loosen its process for recommending drugs and is pressing instead for the NHS to speed up the rollout of approved ...

Less than three weeks after AstraZeneca and Daiichi Sankyo reported positive results for oncology powerhouse Enhertu in a ...

The trial’s primary endpoint is pCR, with secondary endpoints including event-free survival (EFS), overall survival, safety, ...

A mineralocorticoid receptor antagonist that blocks excess aldosterone and reduces fluid volumes, spironolactone is the ...

AstraZeneca (AZ) and Daiichi Sankyo have shared positive results from a late-stage study of their HER2-directed antibody drug ...

AstraZeneca and Daiichi Sankyo’s Enhertu followed by THP showed an improved safety profile vs. standard of careFirst Phase III trial to demonstrate benefit of Enhertu in early breast cancer Positive ...

Narrow-moat Daiichi Sankyo is a Japanese drugmaker with a global footprint and cutting-edge development platform for antibody drug conjugates. As an established pharmaceutical company with a long ...

The famous trees, and the festival associated with their blossoming each spring, is part of a tradition for the global pharmaceutical company.

The Delhi High Court is reviewing RHC Healthcare's challenge to the 'Fortis' trademark sale to Fortis Healthcare, alleging undervaluation. RHC seeks an independent valuation, claiming the Rs 200 crore ...